Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810281 | 0.92 | LTA4H (0.41) | MKNK1MKNK2RAD52PKMSTAT6 | |
| SCHEMBL2808422 | 0.87 | MRGPRX1 (0.40) | MKNK1MKNK2OGAROCK1HRH1 | |
| SCHEMBL2810525 | 0.87 | MRGPRX1 (0.49) | HRH1HRH4 | |
| SCHEMBL2813867 | 0.86 | CLPP (0.40) | HRH1HRH4 | |
| SCHEMBL2816666 | 0.86 | KDM4E (0.41) | OGAROCK1HRH1HRH4 | |
| SCHEMBL14405859 | 0.86 | HRH4 (0.41) | HRH1HRH4 | |
| SCHEMBL2812914 | 0.85 | CLPP (0.40) | IGF1RHRH1HRH4 | |
| SCHEMBL2816727 | 0.85 | OGA (0.39) | OGATYRO3PIK3CAIGF1RFGFR1 | |
| SCHEMBL2811941 | 0.85 | CLPP (0.41) | HRH1HRH4STAT6 | |
| SCHEMBL2812078 | 0.84 | CLPP (0.40) | HRH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | MKNK1 1013/4885MKNK2 1176/4885OGA 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.